Moderna (MRNA)
(Delayed Data from NSDQ)
$116.07 USD
-0.38 (-0.33%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $115.91 -0.16 (-0.14%) 7:16 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRNA 116.07 -0.38(-0.33%)
Will MRNA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
Play Likely Earnings Beat With 5 Top-Ranked Stocks
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Other News for MRNA
Tesla, Archer Aviation rise; Eli Lilly falls, Tuesday, 7/2/2024
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine
IN BRIEF: Moderna gets EMA marketing nod for mResvia vaccine
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet